ReviewCancer immunology, immunotherapy : CII2012
Regulatory dendritic cells in the tumor immunoenvironment.
Review in Cancer immunology, immunotherapy : CII, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed.
- Stimulation of regulatory dendritic cells suppresses cytotoxic T cell function and alleviates DEN-induced liver injury, fibrosis and hepatocellular carcinoma.Frontiers in immunology · 2025Article
- Overview of dendritic cells subsets and their involvement in immune-related pathological disease.BioImpacts : BI · 2025Review
- Therapeutic Monoclonal Antibodies Targeting Immune Checkpoints for the Treatment of Solid Tumors.Antibodies (Basel, Switzerland) · 2019Review
- Immunoescape the link between emphysema and lung cancer?Journal of thoracic disease · 2019Article
- Review
- STAT3 and NF-κB are Simultaneously Suppressed in Dendritic Cells in Lung Cancer.Scientific reports · 2017Article
- Collagen scaffold microenvironments modulate cell lineage commitment for differentiation of bone marrow cells into regulatory dendritic cells.Scientific reports · 2017Article
- Tumor-derived factors modulating dendritic cell function.Cancer immunology, immunotherapy : CII · 2016Review
- Combined Tumor Cell-Based Vaccination and Interleukin-12 Gene Therapy Polarizes the Tumor Microenvironment in Mice.Archivum immunologiae et therapiae experimentalis · 2015Article
- Immunological Mechanisms of Low and Ultra-Low Dose Cancer Chemotherapy.Cancer microenvironment : official journal of the International Cancer Microenvironment Society · 2015Article
- Intratumoral injection of IFN-alpha dendritic cells after dacarbazine activates anti-tumor immunity: results from a phase I trial in advanced melanoma.Journal of translational medicine · 2015Article
- Nano-gold corking and enzymatic uncorking of carbon nanotube cups.Journal of the American Chemical Society · 2015Article
- Article
- Antitumor effects of recombinant antivascular protein ABRaA-VEGF121 combined with IL-12 gene therapy.Archivum immunologiae et therapiae experimentalis · 2014Article
- Imaging aspects of the tumor stroma with therapeutic implications.Pharmacology & therapeutics · 2014Review
- β-catenin-mediated inhibition of cross-priming: A new mechanism for tumors to evade immunosurveillance.Oncoimmunology · 2013Article
- Immunosuppressive mechanisms of regulatory dendritic cells in cancer.Cancer microenvironment : official journal of the International Cancer Microenvironment Society · 2013Article
- The chemotherapeutic agent topotecan differentially modulates the phenotype and function of dendritic cells.Cancer immunology, immunotherapy : CII · 2013Article
- Carbon nanotubes enhance metastatic growth of lung carcinoma via up-regulation of myeloid-derived suppressor cells.Small (Weinheim an der Bergstrasse, Germany) · 2013Article
- Antisense oligonucleotide treatment enhances the recovery of acute lung injury through IL-10-secreting M2-like macrophage-induced expansion of CD4+ regulatory T cells.Journal of immunology (Baltimore, Md. : 1950) · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
The tumor microenvironment is a pivotal factor in tumorigenesis, and especially in progression, as the pathogenesis of cancer critically depends on the complex interactions between various microenvironmental components. A key component of the tumor immunoenvironment is the infiltration of immune cells, which has been proven to play a dual role in tumor growth and progression. This Janus two-faced function of the tumor immunoenvironment is seen in tumor infiltration by T cells, which correlates with improved patient survival, but also with the homing of multiple subsets of immunoregulatory cells that inhibit the antitumor immune response. Regulatory dendritic cells (regDCs) have recently been shown to be induced by tumor-derived factors and represent a new and potentially important player in supporting tumor progression and suppressing the development of antitumor immune responses. Our recent data reveal that different tumor cell lines produce soluble factors that induce polarization of conventional DCs into regDCs, both in vitro and in vivo. These regDCs can suppress the proliferation of pre-activated T cells and are phenotypically and functionally different from their precursors as well as the classical immature conventional DCs. Understanding the biology of regDCs and the mechanisms of their formation in the tumor immunoenvironment will provide a new therapeutic target for re-polarizing protumorigenic immunoregulatory cells into proimmunogenic effector cells able to induce and support effective antitumor immunity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.